8 results about "Obstructive chronic bronchitis" patented technology

This invention relates to a guinea pig model of chronic obstructive pulmonary disease (COPD) with chronic bronchitis, its preparation method, and its application. Specifically, this invention provides a guinea pig model of COPD with chronic bronchitis, established by subjecting guinea pigs to at least two intratracheal infusions of lipopolysaccharide (LPS) combined with repeated exposure to cigarette smoke. This results in the guinea pigs exhibiting pathophysiological characteristics consistent with those of COPD with chronic bronchitis in terms of cough sensitivity, airway inflammation, airway hypersecretion, lung function, and histopathology. This lays a solid foundation for in-depth research and drug screening of COPD with chronic bronchitis.

Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without limitation, the epithelium (the goblet cells, ciliated pseudostratified columnar epithelial cells, and basal cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The system may be used to treat a variety of pulmonary diseases or disorders such as or associated with COPD (e.g., chronic bronchitis, emphysema), asthma, interstitial pulmonary fibrosis, cystic fibrosis, bronchiectasis, primary ciliary dyskinesia (PCD), acute bronchitis and / or other pulmonary diseases or disorders.

Disclosed is a synthetic, non-naturally occurring 12-amino acid peptide, Lung-specific Targeting Peptide, belonging to the larger class of cell penetrating peptides, for delivery of both diagnostic and potentially therapeutic agents to the lung. Also disclosed are methods of treating pulmonary disease, e.g., chronic obstructive pulmonary disease (COPD), emphysema, chronic bronchitis, asthma, primary ciliary dyskinesia (PCD), cystic fibrosis (CF), and lung cancer.

The utility model discloses a kind of metal frame processing anti-deviation welding equipment, including welding frame, the inside movable mounting of welding frame has reciprocating screw rod, the both sides of reciprocating screw rod are provided with guide vane, the inside movable of welding frame is provided with transmission seat, transmission seat is fixed with welding gun and is inserted in the inside, the end outer side of welding gun is installed with negative pressure hopper, negative pressure hopper includes the fixed disc installed in the end outer side of welding gun, the outside of fixed disc is covered with smoke suction disc, smoke suction disc end is fixedly provided with negative pressure pipe.The metal frame processing anti-deviation welding equipment, smoke suction disc is wide in front and narrow in back, the front end of front width can expand smoke capture range, form larger negative pressure adsorption area near welding gun, effectively cover the smoke diffusion range generated when welding;Reduce workshop smoke escape;Avoid the situation that staff long-term inhalation can cause welder pneumoconiosis, chronic bronchitis, emphysema and other respiratory diseases.

The application discloses a kind of compound pharmaceutical composition containing PDE-3 / 4 inhibitor, pharmaceutical preparation and preparation method and application thereof, belong to medical technology field.For the high adverse reaction risk of existing COPD treatment drug, poor patient compliance, heavy economic burden, lack of compound inhalation preparation suitable for severe patients;And the physicochemical properties of different active ingredients are greatly different, it is difficult to stably disperse, PDE-3 / 4 inhibitor wet heat sterilization is easy to generate impurities and other problems.The composition of the application includes PDE-3 / 4 inhibitor, glucocorticoid / JAK inhibitor anti-inflammatory component and LABA / LAMA long-acting bronchodilator.Using polysorbate 80-hydroxypropyl betacyclodextrin stabilizing system, the wet heat sterilization process is optimized, the sterilization concentration is controlled to be 100mg / mL, the process impurities are greatly reduced, the product purity and safety are improved, and sterile inhalation suspension is prepared, which can be atomized to treat chronic bronchitis related COPD.

The present disclosure is directed to an aqueous therapeutic protein formulation including: (i) one or more therapeutic proteins, wherein the one or more therapeutic proteins include one or more anti-DNABII antibodies or antigen-binding fragments thereof in an amount ranging from 10 to 150 mg / mL; (ii) histidine buffer, (iii) NaCl, and (iv) an aqueous carrier, wherein a pH of the aqueous therapeutic formulation ranges from 5.5-8.0, and wherein the formulation is formulated for respiratory tract delivery and produces particles including the one or more therapeutic proteins upon aerosolization. Methods of generating an aerosol and treating biofilm-associated diseases or disorders, e.g., cystic fibrosis, ventilator-associated pneumonia, and acute exacerbations of chronic obstructive pulmonary disease or chronic bronchitis are also provided.

A novel strain, Lactobacillus paracasei ATG-E1 (Accession No. KCTC 14245BP), and a composition containing the same for preventing or treating respiratory diseases which are caused by fine particulate matter. The Lactobacillus paracasei ATG-E1 strain reduces the number of immune cells bronchoalveolar and lung tissues and inhibits the expression of inflammatory cytokines such as interleukin-17A (IL-17A), tumor necrosis factor-α (TNF-α), macrophage inflammatory protein 2 (MIP2), C-X-C motif chemokine ligand 1 (CXCL-1), macrophage inflammatory protein-α (MIP-1α) or interleukin-6 (IL-6). Therefore, the Lactobacillus paracasei ATG-E1 strain can be used for a treatment or health functional food for various respiratory diseases such as acute and chronic bronchitis, catarrhal bronchitis, bronchitis obliterans, inflammatory bronchitis, bronchial asthma, atopic asthma, non-atopic asthma, atopic IgE-mediated asthma, allergic asthma, non-allergic asthma, chronic bronchoconstriction, acute bronchoconstriction, chronic obstructive pulmonary disease, bronchial adenoma, pulmonary tuberculosis, emphysema, lung abscess, pulmonary fibrosis, lung cancer, airway cancer, bronchoalveolar cancer, and bronchial cancer.

The invention therefore provides methods of treating a respiratory disease characterized by mucus hyper-secretion comprising administering to a human patient in need of such treatment a gamma secretase inhibitor (GSI), wherein the administration of a GSI is effective in reducing mucus in such patient's lungs or inhibiting mucus accumulation in said patient's lungs. In some embodiments, the methods of the invention are effective in treating a respiratory disease selected from the group consisting of cystic fibrosis, chronic obstructive pulmonary disease, primary ciliary dyskinesis, chronic bronchitis, asthma, idiopathic and secondary bronchiectasis, bronchiolitis obliterans, idiopathic pulmonary fibrosis, respiratory infection and mucus accumulation in response to infection. Methods of the invention further include methods of treating cystic fibrosis wherein a GSI is administered to a patient being administered or in need of a CFTR modulator, wherein the mucus in such patient's lungs is reduced or mucus accumulation in such patient's lungs is inhibited.